Analyst firms · Piper Sandler · ALGS

Piper Sandler ALGS price target and rating history

Aligos Therapeutics Inc. (ALGS) · Health Care

Piper Sandler rates Aligos Therapeutics Inc. (ALGS) Overweight with a $3 price target, as of its latest action on Jan 6, 2023. It has published 3 rating actions on ALGS since March 2022, including 1 upgrade and 1 downgrade. Across 3 firms with a ALGS price target in the last 12 months, the median target is $45.

Current rating
Overweight
Price target
$3
Median target, all firms
$45
Actions on ALGS
3

Piper Sandler price target on ALGS

$7.50$4.75$22023202420252026
Piper Sandler price target on ALGS, each point a stated target, March 2022 to January 2023. Targets before January 2023 (divided by 2) are adjusted for a stock split, going by the prior target Piper Sandler restated.

Every Piper Sandler rating on ALGS

How other firms rate ALGS

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
Lake StreetBuy$45May 28, 2026
Cantor FitzgeraldOverweight$20May 21, 2026
JefferiesBuy$48Mar 19, 2026

Questions about Piper Sandler and ALGS

What is Piper Sandler's price target for ALGS?
Piper Sandler's latest stated price target for Aligos Therapeutics Inc. (ALGS) is $3, from its action on Jan 6, 2023.
What is Piper Sandler's rating on ALGS?
Piper Sandler rates ALGS Overweight, a bullish rating, as of Jan 6, 2023.
When did Piper Sandler last change its view on ALGS?
On Jan 6, 2023, Piper Sandler upgrades to Overweight from Neutral, price target $2 to $3.
How does Piper Sandler's ALGS target compare with other analysts?
Across 3 firms with a ALGS price target in the last 12 months, the median target is $45.

More ALGS rating histories

All Piper Sandler ratingsALGS news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.